How to buy Tyra Biosciences stock

Tyra Biosciences is a biotechnology business based in the US. Tyra Biosciences shares (TYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Tyra Biosciences employs 25 staff and has a market cap (total outstanding shares value) of 0.00.

Tyra Biosciences stock price (NASDAQ: TYRA)

Use our graph to track the performance of TYRA stocks over time.

Tyra Biosciences shares at a glance

• Key figures

Information last updated 2023-01-31.

Latest market close	$13.18
52-week range	$4.93 - $13.78
50-day moving average more info button	$7.38
200-day moving average more info button	$7.95
Wall St. target price	$20.00
PE ratio more info button	12.2113
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$0.71

Buy Tyra Biosciences stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Tyra Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tyra Biosciences price performance over time

Historical closes compared with the close of $13.18 from 2023-02-03

1 week (2023-01-31)	24.11%
1 month (2023-01-06)	92.41%
3 months (2022-11-07)	74.80%
6 months (2022-08-05)	27.10%

1 year (2022-02-07)	-0.75%
2 years (2021-02-03)	N/A
3 years (2020-02-03)	N/A
5 years (2018-02-03)	N/A

Is Tyra Biosciences stock undervalued or overvalued?

Valuing Tyra Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tyra Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Tyra Biosciences's P/E ratio

Tyra Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Tyra Biosciences shares trade at around 12x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Tyra Biosciences's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

• BioNTech (BNTX.US): 3.38
• Aptevo Therapeutics (APVO.US): 2.15

Tyra Biosciences financials

Gross profit TTM	$0
Return on assets TTM	-11.37%
Return on equity TTM	-18.13%
Profit margin	0%
Book value	$6.41
Market capitalisation more info button	$365.9 million

TTM: trailing 12 months

Tyra Biosciences share dividends

We're not expecting Tyra Biosciences to pay a dividend over the next 12 months.

You may also wish to consider:

• BioNTech (BNTX.US) (1.33% forward annual dividend yield)

Tyra Biosciences overview

Tyra Biosciences, Inc. , a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Frequently asked questions

What percentage of Tyra Biosciences is owned by insiders or institutions?
Currently 8.497% of Tyra Biosciences shares are held by insiders and 94.724% by institutions. How many people work for Tyra Biosciences?
Latest data suggests 25 work at Tyra Biosciences. When does the fiscal year end for Tyra Biosciences?
Tyra Biosciences's fiscal year ends in December. Where is Tyra Biosciences based?
Tyra Biosciences's address is: 2656 State Street, Carlsbad, CA, United States, 92008 What is Tyra Biosciences's ISIN number?
Tyra Biosciences's international securities identification number is: US90240B1061